CAPTRUST Financial Advisors
XBIT icon

CAPTRUST Financial Advisors’s XBiotech XBIT Stock Holding History

CAPTRUST Financial Advisors’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21
Closed – – 4090
2022
Q2 		$0 Hold
21
– – ﹤0.01% 5166
2022
Q1 		$0 Hold
21
– – ﹤0.01% 5160
2021
Q4 		$0 Buy
+21
New +$273 ﹤0.01% 4935

Other funds holding XBIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CAPTRUST Financial Advisors's XBIT Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of XBiotech (XBIT) in Q3 2022, closing a stake of 21 shares.

CAPTRUST Financial Advisors first reported a position in XBIT in Q4 2021 and held it in 3 quarters. The position peaked at $0 in Q2 2022. 45 funds tracked by Wall St. Rank hold XBIT as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining XBiotech position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 21 XBiotech shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in XBiotech in Q4 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's XBiotech position peaked at $0 in Q2 2022.
  • 45 funds tracked by Wall St. Rank held XBiotech as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.